AiCuris starts its first pivotal clinical phase 3 trial with pritelivir for the treatment of herpes simplex virus infections in immunocompromised subjects based on efficacy and safety data from a phase 2 trial
You are currently viewing a placeholder content from Elfsight. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
